- Crossmark names Janet Carter-Smith VP
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- GSK can ship four-strain flu vaccine
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
LOUISVILLE, Ky. — US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.
The company announced the launch of Alsuma auto-injector (sumatriptan), which injects the drug sumatriptan under the skin via a single-use, prefilled auto injector. The company is selling the drug under a licensing agreement from King Pharmaceuticals.
“Migraine headaches continue to be a significant problem for more than 30 million Americans, nearly half of whom are undiagnosed,” said Dennis O’Brien, president of King subsidiary Meridian Medical Technologies. “Alsuma is a natural extension of King’s existing portfolio of acute drug-delivery products.”
The U.S. market for sumatriptan was about $203 million during the 12-month period ended in March 2010, according to IMS Health.